_1584095491997.png?format=webp&height=120&width=120){kind=logo}
About aMoon
aMoon is a venture capital firm founded in 2016. It is primarily based out of Ra'anana, Israel. As of Jun 2026, aMoon is an active investor, having invested in 63 companies, with 7 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series B round of Connie Health Overall, aMoon portfolio has seen 2 unicorns, 11 IPOs and 5 acquisitions including key companies like Omada, Seer and Mammoth. A lot of funds co-invest with aMoon, with names like Fidelity Investments sharing a substantial percentage of its portfolio. aMoon has team of 20 people including 7 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 6 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
aMoon's List of Top Investments
aMoon has a portfolio of 63 companies, including 2 unicorns. Their most notable investments are in Igentify and Scipher Medicine.Their portfolio spans across United States, Israel, Switzerland and 2 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 12 other sectors, across stages such as Series A, Series B and 6 more. Here is the list of top investments by aMoon:
1. Omada
Provider of virtual care programs to manage chronic diseases. The company provides access to personal health coaches and specialists for virtual programs to deliver personalized interventions for prediabetes, diabetes, hypertension, and musculoskeletal issues.
Key facts about Omada
- Founded Year: 2011
- Location: San Francisco (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $450M
- Employee Count: 987 as on May 31, 2026
- Investors: Fidelity Investments, Carriage House Rock and 44 Others
- Latest Funding Round: Series E, Feb 23, 2022, $*****
- Highlight: Public
2. Seer
Developer of proteomics platform for early detection of cancer and neurological diseases. The company has developed a platform Proteograph which analyses the proteomics information and integrates it with genomics and other health data. Using this data it is developing liquid biopsy products for the early detection of cancer and neurological diseases.
Key facts about Seer
- Founded Year: 2017
- Location: San Francisco (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $128M
- Employee Count: 152 as on May 31, 2026
- Investors: HTIF, Fidelity Investments and 15 Others
- Latest Funding Round: Series D, Jul 22, 2020, $*****
- Highlight: Public
3. Ibex
Provider of AI-powered diagnostic solutions for pathology. The company has developed an analytical and diagnosis platform called the GALEN platform which assists with treatment diagnosis and planning. Other products such as First Read and Second Read use AI technology for the diagnosis of cancer based on pathological image analysis. The platform uses computer vision-based image analysis and machine learning technologies in digital pathology.
Key facts about Ibex
- Founded Year: 2016
- Location: Tel Aviv (Israel)
- Stage: Series C
- Total Funding till date: $114M
- Employee Count: 97 as on May 31, 2026
- Investors: Kreos Capital, Planven Entrepreneur Ventures and 6 Others
- Latest Funding Round: Series C, Sep 06, 2023, $*****
- Highlight: Editors' Pick
4. Eleos Health
AI-based behavioral health diagnosis and management system for providers. The company's technology works as an ambient scribe integrating seamlessly with existing workflows and electronic health records via a browser extension. I simplifies documentation, speeding note submission, and enhancing audit compliance via AI-driven flagging of issues.
Key facts about Eleos Health
- Founded Year: 2019
- Location: Boston (United States)
- Stage: Series C
- Total Funding till date: $126M
- Employee Count: 289 as on May 31, 2026
- Investors: Menlo Ventures, Arkin and 16 Others
- Latest Funding Round: Series C, Jan 22, 2025, $*****
- Highlight: Editors' Pick
Provider of precision medicine based on liquid biopsy test. The company's platform identifies which drug will work based on the patient's fundamental blood test report. It offers PrismRA is a blood-based test that predicts patients respond to anti-TNF therapy before the drug is prescribed. The company focuses on autoimmune, neurological, and cardiovascular diseases.
Key facts about Scipher Medicine
- Founded Year: 2014
- Location: Waltham (United States)
- Stage: Series D
- Total Funding till date: $233M
- Employee Count: 56 as on May 31, 2026
- Investors: Cowen, Laurion Capital and 14 Others
- Latest Funding Round: Series D, May 02, 2024, $*****
- Highlight: Editors' Pick
aMoon's Year-on-Year Investment Trends
aMoon has invested in 63 companies over the last 9 years, with an average of 4 new investments annually in the last 5 years. In 2025, it made 7 investments, while as of Jun 2026, it has made 2 investments in this year. Its most recent first time investment was in Connie Health and most recent follow-on round was in Lyfegen.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 2 | 0 | 2 |
2025 | 7 | 0 | 7 |
2024 | 2 | 3 | 5 |
2023 | 2 | 2 | 4 |
2022 | 5 | 5 | 10 |
2021 | 7 | 4 | 11 |
2020 | 8 | 2 | 10 |
2019 | 11 | 0 | 11 |
2018 | 5 | 1 | 6 |
2017 | 3 | 0 | 3 |
aMoon's Investments by Stage
aMoon has made 15 investments in Series A stage with an average round size of $24M, 14 investments in Series B stage with an average round size of $40.8M and 11 investments in Series C stage with an average round size of $53.8M.Stage of entry | No. of Investments |
|---|---|
Series A | 15 |
Series B | 14 |
Series C | 11 |
Seed | 4 |
Series E | 3 |
Others | 5 |
Note: We have considered here, only first round of investments
aMoon's Investments by Sector
aMoon has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, Enterprise Applications, High Tech and Vertical SaaS. Notably, it has invested in 53 Tech companies, 49 Enterprise (B2B) companies, 20 Software companies and at least 9 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 32 |
HealthTech | 17 |
Enterprise Applications | 12 |
High Tech | 11 |
Vertical SaaS | 5 |
Others | 21 |
Note: We have considered here, only first round of investments
aMoon's Investments by Geography
aMoon has made most investments in United States (27), followed by Israel where it has made 21 investments.Country | No. of Investments |
|---|---|
United States | 27 |
Israel | 21 |
Switzerland | 2 |
France | 1 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
aMoon's recent investments
aMoon has made 2 investments in 2026 so far - Connie Health and Atom Computing.Here are the most recent investments by aMoon:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 18, 2026 | United States | Series B | 6804 | [+2] | |
Jun 16, 2026 | United States | Series C | 1577 | [+6] | |
Dec 09, 2025 | United States | Series A | 6904 | ||
Oct 16, 2025 | France | Series A | 1295 | [+9] | |
Aug 19, 2025 | United States | Series C | 7288 | [+4] |
Unicorns in aMoon's Portfolio
aMoon has 2 unicorns in its portfolio - Mammoth and Biosplice. The most recent unicorn in their portfolio is Mammoth. It became a unicorn in 2021, 1 years after aMoon first invested in it.Here is a list of unicorns in aMoon's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
65 | Provider of molecular diagnostics platform by using CRISPR technology | 2017 | Brisbane | Series D | sosyypi | ||
42 | Developer of therapeutics modulating alternative splicing for disease treatment | 2008 | San Diego | Series B | wdseknx |
IPOs and Publicly Listed companies in aMoon's Portfolio
11 of aMoon's portfolio companies have become public. Omada got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jun 2025 at marketcap of $1.06B and Amylyx Pharmaceuticals got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $1.07B.Here are aMoon's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 06, 2025 | Feb 23, 2022 | Series E | 5324 | |
Jan 07, 2022 | Jul 20, 2021 | Series C | 3527 | |
Jul 23, 2021 | Oct 01, 2020 | Series F | 1402 | |
Jul 22, 2021 | Mar 23, 2021 | Series E | 6636 | |
Feb 25, 2021 | Dec 09, 2020 | Series E | 7290 |
Acquired companies in aMoon's Portfolio
5 companies from aMoon's portfolio have been acquired. The most recent acquisition was MetaSight in Feb 2026 by Guardant Health for $*****.Here are aMoon's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 20, 2026 | Nov 13, 2024 | Series A | 1020 | |
Dec 03, 2025 | - | - | 5435 | |
Nov 22, 2023 | May 07, 2017 | Series C | 4617 | |
Dec 02, 2022 | Sep 18, 2019 | Seed | 5555 | |
Aug 10, 2021 | Jun 07, 2018 | Series C | 1623 |
Team profile of aMoon
aMoon has a team of 20 members including 7 Partners, 1 Venture Partner and 2 Principals located in Israel. aMoon's team does not sit on the board of any company as of now.Here is a list of top team members in aMoon:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Tel Aviv | - | ||
Partner | Tel Aviv | - | ||
Partner | Tel Aviv | - | ||
Partner | Rehovot | - | ||
Partner | Jerusalem | - | ||
Partner | Tel Aviv | - | ||
Partner | Israel | - | ||
Venture Partner | Israel | - | - | |
Principal | Israel | - | - | |
Principal | Israel | - |
Co-investors of aMoon
Over the past 9 years, 381 investors have co-invested in aMoon's portfolio companies. This includes funds and angels.
- Invested before aMoon: HHS, Khosla Ventures and 162 others have invested in rounds before aMoon. There are 3 companies where HHS has invested before aMoon and 3 companies where Khosla Ventures has invested before aMoon.
- Top Co-investors of aMoon: 144 investors entered a company along with aMoon. These include investors like Fidelity Investments (3 companies).
- Invested after aMoon: A total of 73 investors have invested in aMoon's portfolio after their investments. Top Investors include Samsung NEXT (2 companies), Redmile Group (2 companies) and Myeloma Investment Fund (2 companies).
Recent News related to aMoon
•
Lin Health Secures $11 Million Series A Funding to Expand Virtual Chronic Pain Recovery PlatformPR Newswire•Dec 09, 2025•Proofpoint Capital, Osage Venture Partners, Lin Health, aMoon and 5 others
•
Adcytherix Raises €105 Million to Advance Antibody-Drug Conjugate PortfolioGlobeNewswire•Oct 16, 2025•Adcytherix, Bpifrance, Angelini Ventures, Citadel and 4 others
•
AP Iantrek Secures $42M Series C for AlloFlo™ Uveo Launch and Pipeline ExpansionBakersfield•Aug 20, 2025•Iantrek, Sectoral, Visionary Ventures, Civilization Ventures and 3 others
•
Positive Development Raises $51.5M to Expand Autism Therapy ModelBusiness Wire•Aug 06, 2025•Positive Development, B Capital, Healthworx, aMoon and 2 others
•
MAGENTIQ EYE Secures Series A Funding Led by aMoon to Advance AI-Powered GastroenterologyPR Newswire•Jul 30, 2025•Namarel Ventures, Norgine, Nina Capital, aMoon and 3 others
•
Character Biosciences gains $93m for precision eye disease therapiesPharmaceutical Technology•Mar 27, 2025•Character Biosciences, Luma Group, aMoon, Bausch & Lomb
•
Character Biosciences Secures $93 Million in Series B Funding to Advance Precision Medicine for Progressive Eye DiseasesVision Monday•Mar 27, 2025•Character Biosciences, aMoon, Luma Group, Bausch & Lomb and 8 others
•
Character Biosciences Achieves Oversubscribed Series BInside Precision Medicine•Mar 26, 2025•Character Biosciences, aMoon, Bausch & Lomb, Thomas Jefferson University and 4 others
•
Lutris Pharma Raises $30M in FundingFinSMEs•Jan 28, 2025•Lutris Pharma, Columbus Venture Partners, Pontifax, Peregrine Ventures and 1 other
•
Lutris Pharma gets $30M to boost anti-cancer drug efficacy.PR Newswire•Jan 28, 2025•Lutris Pharma, Columbus Venture Partners, Pontifax, Peregrine Ventures and 1 other
